-
Something wrong with this record ?
The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients
P. Dvorak, D. Lysak, S. Vokurka, K. Michalova, I. Sarova, A. Jonasova, M. Hruba, A. Rykovska, I. Subrt,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23949951
DOI
10.1002/hon.2089
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Gene Rearrangement MeSH
- Middle Aged MeSH
- Humans MeSH
- Chromosomes, Human, Pair 11 * MeSH
- Chromosomes, Human, Pair 2 * MeSH
- Myelodysplastic Syndromes genetics pathology MeSH
- Prognosis MeSH
- Myeloid-Lymphoid Leukemia Protein genetics MeSH
- Aged MeSH
- Translocation, Genetic * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The translocation t(2;11)(p21;q23) is associated with de novo myelodysplastic syndromes (MDS) and has an overall frequency of approximately 1%. The outcome of MDS patients with this translocation is not clear until now, because most of the clinical data addressing the t(2;11)(p21;q23) has been collected without investigating the status of the mixed lineage leukemia (MLL) gene. In this report, we present seven new patients with MDS diagnosis and the t(2;11)(p21;q23) in bone marrow cells; all of them without MLL gene rearrangement. They were found in two databases consisting of 1185 patients of two Czech institutions. These patients tended to be younger and showed a strong male predominance. A cytological and histological assessment of bone marrow at diagnosis revealed only mild MDS with marked dysplasia in megakaryopoiesis. Similar to other primary abnormalities in MDS (e.g. deletion of 11q), the t(2;11)(p21;q23) was frequently associated with deletion of 5q. Our results stress the common clinicopathological features of this entity and indicate that the t(2;11)(p21;q23) may be associated with a good prognosis for MDS patients (median survival 72 months).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008576
- 003
- CZ-PrNML
- 005
- 20150325104310.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/hon.2089 $2 doi
- 035 __
- $a (PubMed)23949951
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dvorak, Pavel $u Institute of Medical Genetics, University Hospital Pilsen, Pilsen, Czech Republic.
- 245 14
- $a The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients / $c P. Dvorak, D. Lysak, S. Vokurka, K. Michalova, I. Sarova, A. Jonasova, M. Hruba, A. Rykovska, I. Subrt,
- 520 9_
- $a The translocation t(2;11)(p21;q23) is associated with de novo myelodysplastic syndromes (MDS) and has an overall frequency of approximately 1%. The outcome of MDS patients with this translocation is not clear until now, because most of the clinical data addressing the t(2;11)(p21;q23) has been collected without investigating the status of the mixed lineage leukemia (MLL) gene. In this report, we present seven new patients with MDS diagnosis and the t(2;11)(p21;q23) in bone marrow cells; all of them without MLL gene rearrangement. They were found in two databases consisting of 1185 patients of two Czech institutions. These patients tended to be younger and showed a strong male predominance. A cytological and histological assessment of bone marrow at diagnosis revealed only mild MDS with marked dysplasia in megakaryopoiesis. Similar to other primary abnormalities in MDS (e.g. deletion of 11q), the t(2;11)(p21;q23) was frequently associated with deletion of 5q. Our results stress the common clinicopathological features of this entity and indicate that the t(2;11)(p21;q23) may be associated with a good prognosis for MDS patients (median survival 72 months).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a lidské chromozomy, pár 11 $7 D002880
- 650 12
- $a lidské chromozomy, pár 2 $7 D002889
- 650 _2
- $a genová přestavba $7 D015321
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myelodysplastické syndromy $x genetika $x patologie $7 D009190
- 650 _2
- $a protoonkogenní protein MLL $x genetika $7 D051788
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a translokace genetická $7 D014178
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lysak, Daniel
- 700 1_
- $a Vokurka, Samuel
- 700 1_
- $a Michalova, Kyra
- 700 1_
- $a Sarova, Iveta
- 700 1_
- $a Jonasova, Anna
- 700 1_
- $a Hruba, Martina
- 700 1_
- $a Rykovska, Anna
- 700 1_
- $a Subrt, Ivan
- 773 0_
- $w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 32, č. 2 (2014), s. 82-6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23949951 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150325104559 $b ABA008
- 999 __
- $a ok $b bmc $g 1065849 $s 891376
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 32 $c 2 $d 82-6 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
- LZP __
- $a Pubmed-20150306